rs397507697
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 1P and 0B. PM4_Supporting
The NM_000059.4(BRCA2):c.3900_3902delGAC(p.Met1300_Thr1301delinsIle) variant causes a disruptive inframe deletion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000109 in 1,553,890 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000078 ( 0 hom. )
Consequence
BRCA2
NM_000059.4 disruptive_inframe_deletion
NM_000059.4 disruptive_inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.670
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM4
Nonframeshift variant in NON repetitive region in NM_000059.4. Strenght limited to Supporting due to length of the change: 1aa.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.3900_3902delGAC | p.Met1300_Thr1301delinsIle | disruptive_inframe_deletion | 11/27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.3531_3533delGAC | p.Met1177_Thr1178delinsIle | disruptive_inframe_deletion | 11/27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.3900_3902delGAC | non_coding_transcript_exon_variant | 10/26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152158Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
6
AN:
152158
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000149 AC: 3AN: 200696Hom.: 0 AF XY: 0.0000182 AC XY: 2AN XY: 109634
GnomAD3 exomes
AF:
AC:
3
AN:
200696
Hom.:
AF XY:
AC XY:
2
AN XY:
109634
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000785 AC: 11AN: 1401614Hom.: 0 AF XY: 0.00000576 AC XY: 4AN XY: 693940
GnomAD4 exome
AF:
AC:
11
AN:
1401614
Hom.:
AF XY:
AC XY:
4
AN XY:
693940
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152276Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74460
GnomAD4 genome
AF:
AC:
6
AN:
152276
Hom.:
Cov.:
33
AF XY:
AC XY:
2
AN XY:
74460
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jan 11, 2024 | This variant causes an in-frame deletion of Met1300 and Thr1301 and the insertion of isoleucine in exon 11 located in the BRCA2 protein. Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been observed in an individual affected with ovarian cancer (PMID: 11180606) and in a family affected with breast and/or ovarian cancer (PMID: 22762150). This variant has been identified in 7/232092 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Mar 02, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Dec 18, 2017 | - - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 23, 2023 | This variant causes an in-frame deletion of Met1300 and Thr1301 and the insertion of isoleucine in exon 11 located in the BRCA2 protein. To our knowledge, functional studies have not been performed for this variant. This variant has been observed in individuals affected with breast or ovarian cancer (PMID: 11180606, doi.org/10.1515/tjb-2019-0424) and in a family affected with breast and/or ovarian cancer (PMID: 22762150). This variant has been identified in 7/232092 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 29, 2023 | The c.3900_3902delGAC variant (also known as p.M1300_T1301delinsI) is located in coding exon 10 of the BRCA2 gene. This variant results from an in-frame GAC deletion at nucleotide positions 3900 to 3902. The methionine ant threonine residues at codons 1300 and 1301 are deleted and are replaced by isoleucine, an amino acid with highly similar properties. This alteration has been reported in a French breast and/or ovarian cancer family (Lecarpentier J et al. Breast Cancer Res. 2012 Jul 3;14(4):R99). The amino acid region is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 01, 2018 | Variant summary: BRCA2 c.3900_3902delGAC (p.Met1300_Thr1301delinsIle) results in an in-frame deletion that is predicted to remove one amino acid from the encoded protein. The variant allele was found at a frequency of 2.6e-05 in 228420 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3900_3902delGAC has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer (Demange_2001, Lecarpentier_2012). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with other pathogenic variant(s) have been reported (BRCA1 c.5030_5033delCTAA, p.Thr1677IlefsX2 via UMD), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 14, 2023 | The BRCA2 c.3900_3902del (p.Met1300_Thr1301delinsIle) variant has been reported in the published literature in individuals with ovarian cancer (PMID: 11180606 (2001)), breast cancer (PMID: 22762150 (2012), an aggressive parathyroid neoplasm (PMID: 36900297 (2023)), and an unspecified cancer (PMID: 35534704 (2022)). The frequency of this variant in the general population, 0.00013 (3/22978 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. " - |
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | This variant, c.3900_3902del, is a complex sequence change that results in the deletion of 2 and insertion of 1 amino acid(s) in the BRCA2 protein (p.Met1300_Thr1301delinsIle). This variant is present in population databases (rs397507697, gnomAD 0.02%). This variant has been observed in individual(s) with breast cancer, atypical parathyroid tumor (PMID: 11180606, 22762150, 23096105). However, in one of these individuals a pathogenic allele was identified in the BRCA1 gene, which suggests that this c.3900_3902del change in BRCA2might not be the primary cause of disease in this individual. This variant is also known as "4128del3" and "M1306I, T1307del". ClinVar contains an entry for this variant (Variation ID: 51555). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at